Influence of leukemia P388 on plasma concentration-time profiles of bendamustine in B6D2F1 mice.
It was the aim of this study to investigate whether leukemia P388 being an important murine transplantation tumor may alter the plasma concentration-time profiles of the alkylating antineoplastic agent bendamustine (1) in mice. In an advanced tumor stage the rapid decline of 1 plasma levels was found to be retarded in tumor-bearing in comparison to tumor-free animals both after i.v. and p.o. drug administration. These changes cannot be explained by the neoplasia-related depression of drug metabolism whereas the 1-containing ascitic fluid may be a possible reason for the prolonged drug levels in plasma. After p.o. administration of 1, the bioavailability of the drug was found to be increased in the leukemia-bearing animals.
Amlacher
R
R
Institute of Microbiology and Experimental Therapie Jena.
Weber
H
H
Preiss
R
R
Hoffmann
H
H
D000284:Administration, Oral; D000818:Animals; D000069461:Bendamustine Hydrochloride; D005260:Female; D007275:Injections, Intravenous; D007941:Leukemia P388 / Q000378:metabolism*; D051379:Mice; D008815:Mice, Inbred Strains; D009588:Nitrogen Mustard Compounds / Q000493:pharmacokinetics*
D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride